Sangamo BioSciences news from FierceBiotech
NewsSangamo buoyed by positive mid-stage data
Shares of Sangamo BioSciences were buoyed by positive preliminary data from a small mid-stage study of SB-509. The drug is being tested as a therapy for severe diabetic neuropathy. In the study, five Read more...
ALSO NOTED: Genta places notes;Vaccine research blasts off; and much more...
> Genta announced that it has struck definitive agreements with investors to place senior secured convertible notes due in 2010 totaling in aggregate up to $40 million in gross proceeds before Read more...
SPOTLIGHT: Sangamo targets gene manipulation
Forbes has highlighted the development work of Sangamo BioSciences, which has a "hefty" pipeline of drug candidates in development that use zinc-finger DNA binding proteins to manipulate genes for a Read more...
Sangamo shares leap on stem cell tech advance
Shares of Sangamo BioSciences leapt more than 12 percent--to a 52-week high--after researchers published a new study in Nature Biotechnology indicating that its technology could be used to modify Read more...
| Press ReleasesPRESS RELEASE: Sangamo BioSciences and Sigma-Aldrich Announce Nature Biotechnology Study Sangamo BioSciences and Sigma-Aldrich Announce Nature Biotechnology Study Demonstrating Zinc Finger Technology for Modification of Human Stem Cells Application of ZFN Technology in Stem Cells has Read more... |
Get more Sangamo BioSciences coverage at:
Paid Research Reports
- Leading Drug Delivery Companies and Technologies: Competitive landscape, company profiles and technological developments
- Drug Repositioning Strategies - Serendipity by design
- eHealthInsight Series: Online Patient Recruitment Strategies - Optimizing the clinical trial process
- Pricing & Reimbursement - Seven Major Markets Update
- Innovative Clinical Trial Design and Management: Trends, success stories and impact upon R&D budgets